AD/PD™ Neuro Talks – Early Alzheimer’s: Biomarkers in Practice

In collaboration with EISAI Inc. and Biogen, AD/PD™ presents a new expert-interview series exploring the clinical and scientific developments transforming the future of early Alzheimer’s disease (AD) diagnosis and care.

Recorded at AD/PD™ 2026, these relaxed and insightful interviews bring together leading international experts and host Dr. Samuel Lockhart to discuss the evolving role of blood-based biomarkers (BBMs) across clinical practice and research.

About the Series

This four-episode series examines key topics surrounding early AD and BBM implementation through expert-led conversations designed for healthcare professionals involved in neurology, dementia care, and cognitive disorders.

Each episode offers practical insights, current evidence, and discussion around the opportunities and challenges facing clinicians today.

Meet Your Host

Dr. Samuel Lockhart is Senior Scientific Director at Perceptive and Adjunct Associate Professor at Wake Forest School of Medicine. His work focuses on neurodegenerative diseases, biomarker development, and advancing innovative approaches to AD research and clinical care.

Featured Speakers

• Dr. Simon Ducharme – Neuropsychiatrist and Clinician-Scientist, McGill University, Montreal, Quebec, Canada
• Dr. Noa Bregman – Director of the Cognitive Neurology Unit, Tel Aviv Medical Center, Tel Aviv, Israel
• Dr. Suzanne Schindler – Associate Professor, Washington University School of Medicine in St. Louis, USA
• Dr. Sid O’Bryant – Executive Director of the Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, USA
• Prof. Charlotte Teunissen – Professor in Neurochemistry, Amsterdam UMC, Amsterdam, The Netherlands

Featured Speaker: Simon Ducharme, MD, FRCP(C)

In this first episode we discuss the growing importance of understanding preclinical Alzheimer’s disease (AD) within the broader AD continuum.

The conversation explores evolving definitions, clinical implications, and how advances in biomarkers and early identification may influence future approaches to diagnosis and care.

Discussion Highlights

• Understanding preclinical AD
• Defining the AD continuum
• Clinical implications of earlier detection
• Emerging perspectives in research and practice

Featured Speaker: Dr. Noa Bregman

This episode explores the clinical importance of diagnosing Alzheimer’s disease (AD) at its earliest stages and the approaches that can support timely and accurate identification.

The conversation examines how early diagnosis can inform clinical decision-making, patient counseling, and care planning, while addressing the challenges of distinguishing early AD from normal aging and other cognitive conditions.

Discussion Highlights

• Clinical value of early diagnosis for patients and caregivers
• Distinguishing early AD from normal aging
• Defining early AD diagnosis and its role in clinical practice
• Biomarkers in early diagnosis

Featured Speakers: Dr. Suzanne Schindler and Dr. Sid O’Bryant

This episode explores the growing role of blood-based biomarkers (BBMs) in Alzheimer’s disease (AD) care and their transition towards routine clinical practice.

The conversation examines practical considerations for selecting and using BBMs, their integration into clinical decision-making, and the opportunities and challenges of implementing these tests in real-world settings.

Discussion Highlights

• Bringing BBM testing into clinical practice
• Practical considerations for selecting and using BBMs
• Integrating BBMs into clinical decision-making
• Opportunities and challenges in real-world implementation

Featured Speaker: Prof. Charlotte Teunissen

This episode explores the challenges of interpreting blood-based biomarker (BBM) results in Alzheimer’s disease (AD) and the importance of considering findings within the broader clinical picture.

The conversation examines how to understand discordant biomarker results and use BBMs alongside clinical assessments to support informed decision-making.

Discussion Highlights

• Key challenges in interpreting BBM results
• Understanding discordant biomarker findings
• The importance of clinical context
• Using BBMs to support clinical decision-making